Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

(2016) Marc Hafner et al.   NATURE METHODS

Managing risks in drug discovery: reproducibility of published findings

(2016) Aimo Kannt et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

(2016) Junko Murai et al.   Oncotarget

Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function

(2016) Andre Kleensang et al.   Scientific Reports

Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells

(2016) John P Vanden Heuvel et al.   eLife

Replication-induced DNA damage after PARP inhibition causes G2delay, and cell line-dependent apoptosis, necrosis and multinucleation

(2015) Idun Dale Rein et al.   CELL CYCLE

PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway

(2015) F. Engert et al.   MOLECULAR CANCER THERAPEUTICS

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

(2015) José Luis Ordóñez et al.   Oncotarget

Conducting Meta-Analyses inRwith themetaforPackage

(2015) Wolfgang Viechtbauer   Journal of Statistical Software

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma

(2015) Sonja J. Gill et al.   PLoS One

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

(2014) Edwin Choy et al.   BMC CANCER

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

(2014) M. A. Smith et al.   CLINICAL CANCER RESEARCH

Refinement of Experimental Design and Conduct in Laboratory Animal Research

(2014) J. D. Bailoo et al.   ILAR JOURNAL

Policy: NIH to balance sex in cell and animal studies

(2014) Janine A. Clayton et al.   NATURE

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673

(2014) Malcolm A. Smith et al.   PEDIATRIC BLOOD & CANCER

Targeting the DNA Repair Pathway in Ewing Sarcoma

(2014) Elizabeth Stewart et al.   Cell Reports

An open investigation of the reproducibility of cancer biology research

(2014) Timothy M Errington et al.   eLife

Effects of hypoxia on human cancer cell line chemosensitivity

(2013) Sara Strese et al.   BMC CANCER

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation

(2013) Britta Stordal et al.   Molecular Oncology

Power failure: why small sample size undermines the reliability of neuroscience

(2013) Katherine S. Button et al.   NATURE REVIEWS NEUROSCIENCE

Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors

(2013) Robin E. Norris et al.   PEDIATRIC BLOOD & CANCER

PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma

(2012) J. C. Brenner et al.   CANCER RESEARCH

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Atmospheric Oxygen Inhibits Growth and Differentiation of Marrow-Derived Mouse Mesenchymal Stem Cells via a p53-Dependent Mechanism: Implications for Long-Term Culture Expansion

(2012) Siddaraju V. Boregowda et al.   STEM CELLS

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

(2010) V. J. Weston et al.   BLOOD

Guidelines for accurate EC50/IC50 estimation

(2010) J. L. Sebaugh   PHARMACEUTICAL STATISTICS